ATAI Life Sciences Files 8-K Report

TL;DR

ATAI Life Sciences filed an 8-K on 10/20/2025 for Reg FD and other events. No major news yet.

AI Summary

On October 20, 2025, ATAI Life Sciences N.V. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and other events, along with financial statements and exhibits. No specific financial figures or material events were detailed in the provided text.

Why It Matters

This 8-K filing indicates that ATAI Life Sciences N.V. is providing updates or disclosures to the SEC, which could be relevant for investors monitoring the company's regulatory compliance and operational announcements.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without specific material disclosures of significant financial or operational changes, indicating a low immediate risk.

Key Players & Entities

• ATAI Life Sciences N.V. (company) — Registrant
• October 20, 2025 (date) — Date of earliest event reported
• 001-40493 (other) — Commission File Number

FAQ

Key Financial Figures

• $5.48 — shares"), at a public offering price of $5.48 per share, less underwriting discounts

Filing Documents

• ef20057467_8k.htm (8-K) — 37KB
• ef20057467_ex99-1.htm (EX-99.1) — 13KB
• image00004.jpg (GRAPHIC) — 3KB
• 0001140361-25-038748.txt ( ) — 188KB
• atai-20251020.xsd (EX-101.SCH) — 4KB
• atai-20251020_lab.xml (EX-101.LAB) — 22KB
• atai-20251020_pre.xml (EX-101.PRE) — 16KB
• ef20057467_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure. On October 20, 2025, ATAI Life Sciences N.V. (the "Company") issued a press titled "atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares." A copy of the press release is being furnished to the Securities and Exchange Commission (the "SEC") as Exhibit 99.1 to this Current Report on Form 8-K ("Form 8-K"). The information in this Item 7.01 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01

Item 8.01. Other Events. On October 20, 2025, the Company announced the closing of the Company's public offering (the "Offering") of 27,283,750 common shares of the Company, nominal value 0.10 per share (the "common shares"), at a public offering price of $5.48 per share, less underwriting discounts and commissions, and inclusive of the closing of the exercise of the underwriters' option in full to purchase an additional 3,558,750 common shares at the public offering price, less underwriting discounts and commissions. The Company intends to use the net proceeds from the Offering, together with existing cash, cash equivalents, short-term investments and other liquid assets, to advance the clinical development across its pipeline of product candidates and programs. This includes funding the planned Phase 3 clinical program for BPL-003 (mebufotenin benzoate) nasal spray through the top-line data readout from the first Phase 3 clinical trial, completing the Phase 2 clinical trial of VLS-01 (buccal film DMT) and completing the Phase 2a study for EMP-01 (oral R-MDMA) as well as for working capital and general corporate purposes. Based on this planned use of proceeds and the Company's current operating plan, the Company estimates that its existing cash, cash equivalents, short-term investments and other liquid assets will be sufficient to fund operations into 2029. Cautionary Note Regarding Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "could," "would," "project," "plan," "potentially," "preliminary," "likely," and the negative of these terms and similar ex

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1* Press Release of ATAI Life Sciences N.V., dated October 20, 2025. 104 Cover Page Interactive Data File (embedded within the inline XBRL document). * Furnished herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: October 21, 2025 By: /s/ Srinivas Rao Name: Srinivas Rao Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR